Skip to content

Nociceptive-Level (NoL)-guided analgia versus standerd practice during general remifentanil/propofol anesthesia in ASA 1-3 patients

Nociceptive-Level (NoL)-guided analgia versus standerd practice during general remifentanil/propofol anesthesia in ASA 1-3 patients

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON27388
Enrollment
80
Registered
2017-02-28
Start date
2016-07-25
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Nociceptive level guided analgesia

Sponsors

Medasense
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Age: 18-80 years; 2. ASA I-II-III 3. Elective open abdominal surgery or laparoscopic assisted abdominal surgery.

Exclusion criteria

Exclusion criteria: 1. Unable to give written informed consent; 2. Use of epidural analgesia or local anesthesia (eg. transversus abdominal plain block, TAP block) 3. Non-elective surgery 4. Pregnancy/lactation; 5. BMI > 35 kg/m2; 6. Uncontrolled preoperative hypo- or hypertension (Mean arterial pressure 100 mmHg) 7. Preoperative Heart rate 90/min; 8. Central nervous system disorder (neurologic/head trauma/uncontrolled epileptic seizures); 9. Illicit substance or alcohol abuse within 30 days; 10. Chronic use of pain medication within 30 days; 11. Chronic use of psychoactive drugs within 30 days; 12. Significant medical condition a. Untreated or persistent peripheral or central cardiovascular disease b. Severe pulmonary disease e.g. COPD gold 4 , FEV 6.0 kPa c. Significant hepatic disease with increased bilirubin, INR or low albumin 13. Beta blocker use

Design outcomes

Primary

MeasureTime frame
1. Opioid and propofol consumption in total dose and dose/min; and 2. Incidence (number of episodes) and total duration of inadequate anesthesia

Secondary

MeasureTime frame
1. Differences in Pk (prediction probability) values of NoL, BIS, HR and MAP for predicting the balance of nociception-anti nociception during the following states • Awake vs. loss of consiousness (LOC) • Anesthesia (after discontinuation of propofol and remifentanil) vs. opening eyes • LOC vs intubation • Normal stimulation vs maximum stimulation (as indicated by the surgeon); 2. Incidence of NoL values 20; 3. Time from reversal of neuromuscular blockade to extubation; 4. Pain and sedation scores, incidence of nausea/vomiting, hemodynamics, respiration and medication use (e.g. opioids and antiemetics) in the recovery room obtained at 15-min interval; 5. PACU: time until Aldrete > 9 (readiness for discharge); 6. Incidence of memory/awareness.

Contacts

Public ContactAlbert Dahan

Leiden University Medical Center (LUMC), Department of Anesthesiology, P.O. Box 9600

a.dahan@lumc.nl+31 (0)71 5262301

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)